Annual Report No : 4
#JBChemandPharma
Like & Retweet for better reach !
Read highlights of annual reports of other companies : valueeducator.com/highlights-of-…
#JBChemandPharma
Like & Retweet for better reach !
Read highlights of annual reports of other companies : valueeducator.com/highlights-of-…
1. Company Overview
JB Chemicals and Pharmaceuticals was established in 1976 and is a leading player in the domestic branded generics space. The company has 5 brands among the top 300 brands in the domestic market.
JB Chemicals and Pharmaceuticals was established in 1976 and is a leading player in the domestic branded generics space. The company has 5 brands among the top 300 brands in the domestic market.
The company sells its finished formulations in India as well as exports it to 30 countries. JB Chemicals and Pharmaceuticals is also involved in contract manufacturing of lozenges. The company ranks among the top 5 manufacturers globally in medicated and herbal lozenges.
It has 7 manufacturing facilities including a dedicated manufacturing facility for medicated lozenges.
2. Manufacturing facilities
JB Chemicals and Pharmaceuticals has 7 manufacturing facilities located in western India.
JB Chemicals and Pharmaceuticals has 7 manufacturing facilities located in western India.
They can manufacture a wide variety of solid and liquid dosage forms
3. Therapeutic areas
The company’s core therapy areas are hypertension, gastroenterology, nephrology, cardiology, dentistry, and pediatrics but they offer a number of formulations in various other therapy areas as well.
The company’s core therapy areas are hypertension, gastroenterology, nephrology, cardiology, dentistry, and pediatrics but they offer a number of formulations in various other therapy areas as well.
4. Revenue split
For the year ended FY21, total revenue was ₹2043 crores. Domestic business accounted for approximately 44% of it while exports accounted for around 40%. API business contributed 4% of revenues and the CMO business contributed 12%.
For the year ended FY21, total revenue was ₹2043 crores. Domestic business accounted for approximately 44% of it while exports accounted for around 40%. API business contributed 4% of revenues and the CMO business contributed 12%.
The domestic business saw a 27% growth against an 18% market growth. JB Chemical and Pharmaceuticals has a 30% market share in their top 5 molecules.
The company is also focusing on chronic therapies and the share of chronic therapies in the overall product mix has been increasing steadily from 36% in FY17 to 46% in FY21.
The international revenues as for FY21 were ₹1127 crores of which international formulations business accounted for 72%, the CMO business accounted for 20% and the remaining 8% came from API.
5. Acquisition of Sanzyme Private Limited
JB Chemicals entered into the fast-growing probiotics, therapeutic nutraceuticals and reproductive health market through the acquisition of Sanzyme, a leading player in the probiotics segment. Post the acquisition,
JB Chemicals entered into the fast-growing probiotics, therapeutic nutraceuticals and reproductive health market through the acquisition of Sanzyme, a leading player in the probiotics segment. Post the acquisition,
JB Chemicals will be amongst the top five probiotics players in the country. The segment is growing at 12-14% and the acquisition creates significant synergies.
Sanzyme operates in the gastroenterology, nephrology, urology and gynecology therapy areas with leading brands such as Sporlac, Lobun, and Gynogen.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
